Drug Database
RA

rabies antiserum

✓ Approved

Shanghai Serum Biotechnology · Polyclonal Antibodies · Polyclonal Antibodies

What is rabies antiserum?

rabies antiserum is a polyclonal antibodies developed by Shanghai Serum Biotechnology. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

CompanyShanghai Serum Biotechnology
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Shanghai Serum Biotechnology

Therapeutic Indications

rabies antiserum is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsRabies✓ Approved

Related Research Articles

PubMedTrends in molecular medicine2026-07-25

Overcoming rabies immune evasion via monoclonal antibody therapeutics.

Uddin Md Jashim MJ, King Jocelyn J, Broder Christopher C CC, Schaefer Brian C BC

Rabies is a lethal acute viral encephalitis caused by neurotropic lyssaviruses, particularly Lyssavirus rabies. The current treatment for rabies exposure involves post-exposure prophylaxis (PEP), which includes the administration of the rabies vaccine and rabies immunoglobulins (RIGs). No effective treatments exist to cure symptomatic rabies. Due to the limited availability and high cost of PEP, tens of thousands of deaths still occur worldwide every year. Monoclonal antibodies (mAbs) represent an effective and economical alternative to RIGs. Moreover, recent preclinical studies have provided evidence that monoclonal antibodies can effectively treat symptomatic rabies, overcoming mechanisms of viral immune evasion. In this review, we critically summarize recent studies, focusing on the treatment of rabies exposures using monoclonal antibodies and the potential of monoclonal antibody-based therapies to combat symptomatic rabies.

PMID 42498606
Read full article →
PubMedOne health (Amsterdam, Netherlands)2026-07-24

One Health implementation for rabies elimination in India by 2030: Progress, governance, challenges, and policy alignment.

Phukan Purabi P

India has committed to eliminating dog-mediated human rabies by 2030 through the National Action Plan for Rabies Elimination (NAPRE), aligned with the global "Zero by 30" target within a One Health framework. Yet nationally representative 2022-23 data indicate that substantial dog-bite exposure and preventable rabies deaths persist despite effective preventive interventions. This commentary argues that India's slow progress reflects implementation gaps, including fragmented governance, weak integrated surveillance, inadequate canine vaccination coverage, inequitable access to timely post-exposure prophylaxis (PEP), and limited multisectoral accountability. Achieving elimination requires operational One Health systems with integrated surveillance, sustained mass dog vaccination, universal intradermal PEP access, and targeted pre-exposure prophylaxis (PrEP) in low PEP access high-risk settings.

PMID 42494549
Read full article →
PubMedCarbohydrate polymers2026-07-24

The O antigen of Klebsiella pasteurii 0.067 lipopolysaccharide: structure, serology and genetic loci organization.

Palusiak Agata A, Maciejewska Anna A, Artyszuk Daria D, Lukasiewicz Jolanta J

Klebsiella pasteurii belongs to Klebsiella oxytoca species complex and corresponds to the Ko4 phylogroup, which was recently recognized as a distinct species. Its reliable identification requires whole-genome sequencing and chromosomal blaOXY variants characteristic of the Ko4 phylogroup can support species-level differentiation. K. pasteurii is isolated from soil, water, plants, animals and human. The recent description of the species as a distinct species has resulted in limited knowledge regarding its virulence factors including O-polysaccharide (OPS). The presented studies focus on a K. pasteurii 0.067 isolate from the urine of a newborn. The strain phenotypic characterization revealed an antibiotic-sensitivity profile and extended spectrum β-lactamases (ESBL)-negative phenotype. The K. pasteurii 0.067 genome sequence analysis revealed the presence of four genes associated with drug resistance (oqxAB, fosA and blaOXY-4-1), kleboxymycin and yersiniabactin encoding genes. Genomic analysis revealed type O2α locus with additional wbbYZ and gml2β clusters. Structural analysis, supported by NMR spectroscopy and mass spectrometry indicated the presence of the O1αβ,2αβ OPS of K. pasteurii 0.067 with non-stoichiometric substitution of terminal β-d-Galp with 3,4-linked S-pyruvic acid (3,4(S)-Pyr), which provides potential epitope recognized by Proteus mirabilis O24 antiserum. It is the first report on the K. pasteurii O antigen structure and its genetic background.

PMID 42493073
Read full article →
PubMedPLoS neglected tropical diseases2026-07-23

Safety and operational feasibility of single versus cocktail rabies monoclonal antibodies for post-exposure prophylaxis in a resource-limited setting.

Fotedar Nidhi N, Ravish Haradanahalli Shankariah HS

Rabies is almost universally fatal once symptoms develop but is preventable through timely post-exposure prophylaxis (PEP). Global shortages of human and equine rabies immunoglobulin (RIG) have led the World Health Organization to recommend human monoclonal antibodies (mAbs) as acceptable alternatives. Comparative real-world data on single-antibody versus two-antibody cocktail mAbs are limited, particularly from endemic, resource-limited settings. A comparative observational study was conducted in a high-volume rabies PEP clinic in India between October 2021 and December 2022. Consecutive patients with category III animal exposures received either a single human anti-rabies mAb (Rabishield; n = 159) or a two-mAb cocktail (Twinrab; n = 159) in combination with WHO-recommended vaccine. Primary outcomes included safety, ease of administration, and operational feasibility. Data were analysed using independent t-tests and chi-square or Fisher's exact tests, with p < 0.05 considered significant. Mean age was 29.7 ± 19.4 years in the Rabishield group and 32.8 ± 20.4 years in the Twinrab group. Ease of infiltration was rated "easy" in 66.7% versus 62.9% of patients (p = 0.63). Local adverse events were uncommon, with pain reported in 2.5% versus 7.5% (p = 0.07) and erythema in ≤ 1.3% of participants. No serious systemic adverse events occurred. Rabishield required more vials per patient (2.28 ± 0.84 vs 2.00 ± 0.69; p = 0.001) and had a higher mean infiltration volume (4.7 ± 1.9 mL vs 4.0 ± 1.6 mL; p < 0.001), while wastage was similar between groups (1.03 ± 0.72 mL vs 1.03 ± 0.69 mL; p = 0.95). Both single and cocktail human anti-rabies mAbs were safe, well tolerated, and operationally feasible in a programmatic setting. The slightly higher volume and vial requirement for Rabishield may have cost and logistics implications. These findings support broader mAb adoption to address RIG shortages in rabies-endemic, resource-limited settings.

PMID 42490664
Read full article →
PubMedFrontiers in tropical diseases2026-07-22

Experiences of piloting integrated bite case management in Zaria Metropolis, Nigeria.

Kia Grace Sabo Nok GSN, Samuel Mathias M, Ferguson Elaine A EA, Ibrahim Ishaq I et al.

Rabies remains a major public health risk in Africa and is estimated to cause over 1,600 deaths annually in Nigeria. Integrated Bite Case Management (IBCM) is recommended as a One Health approach for rabies surveillance but has yet to be implemented within Nigeria. Our aim was to gain epidemiological and operational understanding of implementing IBCM within Sabon Gari Local Government Area (LGA) of Zaria Metropolis, Kaduna State, Nigeria through an implementation research approach. We developed an IBCM protocol with local practitioners and piloted it from April 2023 until December 2024, and analyzed resulting data. We identified very low access to rabies post-exposure prophylaxis (PEP) within the study area. Although incidence of bite patients was low (~0.98/100,000/year, 95% confidence intervals, CI: 0.68-1.42), a large proportion were identified as rabies exposures (41%) and two human rabies deaths occurred (0.11 deaths/100,000/year, 95%CI: 0.031-0.41), corresponding to very low healthcare seeking (0.50 probability of rabies exposures receiving PEP, 95%CI: 0.27-0.86). Investigations triggered by dog bite incidents or community notifications identified probable rabid dogs from clinical signs/history (45% of investigated dogs), with all recoverable samples (8) confirmed positive by rapid testing, including three dogs that died in quarantine. IBCM revealed the dog meat trade as a sentinel for rabies detection, with three rabid dogs sold for consumption. Key aspects of IBCM were refined to improve implementation during the pilot. Piloting IBCM revealed a low incidence of bite presentations reflecting the small dog population (high human: dog ratio) in these communities and very low levels of care seeking among those at risk. We conclude that there is an urgent need to simultaneously improve PEP access and raise awareness about the dangers of rabies. Other critical gaps in rabies control and prevention, include low dog vaccination coverage, limited training in rabies prevention and a lack of resources for surveillance, despite urgent demand and enthusiasm for implementation. The generalizability of our conclusions are limited given our experiences are derived from a single LGA. Nevertheless, this we provide lessons for how to develop IBCM for this local health and veterinary context in accordance with cultural norms and identify considerations for the design and implementation of IBCM elsewhere.

PMID 42482709
Read full article →
PubMedBrain structure & function2026-07-22

Transsynaptic neural circuit mapping of ventral hippocampus motivational control systems.

Klug Molly E ME, Shanmugam Mugil V MV, Huang Haoyang H, Arnold Don D et al.

The ventral hippocampus contributes to food intake regulation and a range of motivational and memory processes, and its dysfunction is associated with several cognitive and behavioral disorders. However, its circuit-level organization remains incompletely understood. Ventral CA1 (CA1v) neurons send projections to several regions involved in motivational control. Here we focus on three major forebrain targets: the nucleus accumbens shell (ACBsh), medial prefrontal cortex (mPFC), and lateral hypothalamic area (LHA). We mapped the upstream and downstream circuitry of CA1v neurons defined by their projections to these target regions in rats using complementary transsynaptic anterograde and retrograde viral tracing approaches. Monosynaptic outputs to ACBsh, mPFC, and LHA were targeted using ATLAS, a novel transsynaptic anterograde viral approach that drives Cre recombinase in neurons receiving synaptic transmission from the CA1v. Second-order projections arising from these defined pathways were then mapped using a Cre-dependent anterograde viral tracing strategy. In parallel, upstream inputs to CA1v neurons projecting to each downstream target were mapped using a conditional retrograde glycoprotein-deleted rabies viral approach. Anterograde tracing revealed both shared and pathway-specific second-order targets, including bidirectional CA1v projections. Retrograde tracing confirmed expected inputs (e.g., CA3) and uncovered previously unrecognized cortical sources that differed across downstream projection-defined CA1v subpopulations. Together, these findings delineate pathway-specific, multi-node circuits linking CA1v neurons to key motivational systems that may inform future therapeutic strategies for disorders involving ventral hippocampal dysfunction.

PMID 42484706
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about rabies antiserum